Literature DB >> 17118988

The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Steven P O'Hara1, Aaron J Small, Jeremy B Nelson, Andrew D Badley, Xian-Ming Chen, Gregory J Gores, Nicholas F Larusso.   

Abstract

While Cryptosporidium parvum infection of the intestine has been reported in both immunocompetent and immunocompromised individuals, biliary infection is seen primarily in adult AIDS patients and is associated with development of AIDS cholangiopathy. However, the mechanisms of pathogen-induced AIDS cholangiopathy remain unclear. Since we previously demonstrated that the Fas/Fas ligand (FasL) system is involved in paracrine-mediated C. parvum cytopathicity in cholangiocytes, we also tested the potential synergistic effects of human immunodeficiency virus type 1 (HIV-1) transactivator of transcription (Tat)-mediated FasL regulation on C. parvum-induced apoptosis in cholangiocytes by semiquantitative reverse transcription-PCR, immunoblotting, immunofluorescence analysis, and immunogold electron microscopy. H69 cells do not express CXCR4 and CCR5, which are receptors required for direct HIV-1 viral infection. However, recombinant biologically active HIV-1-associated Tat protein increased FasL expression in the cytoplasm of cholangiocytes without a significant increase in apoptosis. We found that C. parvum-induced apoptosis was associated with translocation of intracellular FasL to the cell membrane surface and release of full-length FasL from infected H69 cells. Tat significantly (P < 0.05) increased C. parvum-induced apoptosis in bystander cells in a dose-dependent manner. Moreover, Tat enhanced both C. parvum-induced FasL membrane translocation and release of full-length FasL. In addition, the FasL neutralizing antibody NOK-1 and the caspase-8 inhibitor Z-IETD-fmk both blocked C. parvum-induced apoptosis in cholangiocytes. The data demonstrated that HIV-1 Tat enhances C. parvum-induced cholangiocyte apoptosis via a paracrine-mediated, FasL-dependent mechanism. Our results suggest that concurrent active HIV replication, with associated production of Tat protein, and C. parvum infection synergistically increase cholangiocyte apoptosis and thus jointly contribute to AIDS-related cholangiopathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118988      PMCID: PMC1828501          DOI: 10.1128/IAI.01348-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

Review 1.  Multifaceted activities of the HIV-1 transactivator of transcription, Tat.

Authors:  K T Jeang; H Xiao; E A Rich
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

Review 2.  HIV-1 gp120: a novel viral B cell superantigen.

Authors:  J Townsley-Fuchs; M S Neshat; D H Margolin; J Braun; L Goodglick
Journal:  Int Rev Immunol       Date:  1997       Impact factor: 5.311

Review 3.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

Review 4.  Hepatobiliary diseases in patients with AIDS: focus on AIDS cholangiopathy and gallbladder disease.

Authors:  C M Wilcox; K E Mönkemüller
Journal:  Dig Dis       Date:  1998 Jul-Aug       Impact factor: 2.404

5.  In vivo protein transduction: delivery of a biologically active protein into the mouse.

Authors:  S R Schwarze; A Ho; A Vocero-Akbani; S F Dowdy
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

6.  Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.

Authors:  M J Martínez-Lorenzo; A Anel; S Gamen; I Monle n; P Lasierra; L Larrad; A Piñeiro; M A Alava; J Naval
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

7.  Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism.

Authors:  X M Chen; G J Gores; C V Paya; N F LaRusso
Journal:  Am J Physiol       Date:  1999-09

Review 8.  New insights into human cryptosporidiosis.

Authors:  D P Clark
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

9.  Cryptosporidiosis in patients with AIDS: correlates of disease and survival.

Authors:  Y C Manabe; D P Clark; R D Moore; J A Lumadue; H R Dahlman; P C Belitsos; R E Chaisson; C L Sears
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

10.  Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8.

Authors:  S R Bartz; M Emerman
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more
  5 in total

Review 1.  The immunobiology of cholangiocytes.

Authors:  Xian-Ming Chen; Steven P O'Hara; Nicholas F LaRusso
Journal:  Immunol Cell Biol       Date:  2008-05-27       Impact factor: 5.126

2.  HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum.

Authors:  Steven P O'Hara; Aaron J Small; Gabriella B Gajdos; Andrew D Badley; Xian-Ming Chen; Nicholas F Larusso
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

3.  Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513.

Authors:  Ai-Yu Gong; Rui Zhou; Guoku Hu; Jun Liu; Danuta Sosnowska; Kristen M Drescher; Haidong Dong; Xian-Ming Chen
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

4.  Immunostaining of Cryptosporidiosis with Human Immunodeficiency Virus Infection.

Authors:  Eisuke Adachi; Yasutoshi Kido; Yasunori Ota; Tomohiko Koibuchi
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

5.  Enterocyte-innate lymphoid cell crosstalk drives early IFN-γ-mediated control of Cryptosporidium.

Authors:  Jodi A Gullicksrud; Adam Sateriale; Julie B Engiles; Alexis R Gibson; Sebastian Shaw; Zachary A Hutchins; Lindsay Martin; David A Christian; Gregory A Taylor; Masahiro Yamamoto; Daniel P Beiting; Boris Striepen; Christopher A Hunter
Journal:  Mucosal Immunol       Date:  2021-11-08       Impact factor: 8.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.